| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | LDLCQ3 |
| WB Predicted band size | 97 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human HMGCR |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于HMGCR抗体的3篇参考文献的简要总结：
---
1. **文献名称**：*Autoimmune myopathy associated with statin use and anti-HMGCR autoantibodies*
**作者**：Christopher-Stine, L. et al.
**摘要**：该研究首次提出HMGCR抗体与他汀类药物诱导的自身免疫性肌病(如免疫介导坏死性肌病，IMNM)相关，患者表现为进行性肌无力、肌酸激酶升高，且对停用他汀后仍需免疫抑制治疗。
---
2. **文献名称**：*Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy*
**作者**：Mammen, A.L. et al.
**摘要**：研究验证了HMGCR抗体作为IMNM的生物标志物，发现抗体阳性患者中多数有长期他汀暴露史，病理特征为肌肉坏死但炎症浸润较少，提示抗体在诊断中的特异性。
---
3. **文献名称**：*Clinical characteristics and treatment outcomes of anti-HMGCR antibody-positive necrotizing myopathy*
**作者**：Albayda, J. et al.
**摘要**：分析HMGCR抗体阳性患者的临床特征，发现其肌无力症状常累及四肢近端和颈部屈肌，多数患者需联合免疫治疗(如糖皮质激素+免疫抑制剂)，且抗体水平与疾病活动性相关。
---
4. **文献名称**：*HMGCR antibody-associated myopathy: A treatable condition in patients with statin exposure*
**作者**：Pinal-Fernandez, I. et al.
**摘要**：强调早期识别HMGCR抗体阳性肌病的重要性，及时停用他汀并启动免疫治疗可改善预后;部分未使用他汀的患者(如儿童)也可能因遗传易感性产生该抗体。
---
以上文献均聚焦于HMGCR抗体在肌病中的病理机制、诊断价值及临床管理，为理解该自身免疫性疾病提供了关键证据。
**Background of HMGCR Antibodies**
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase) is a key enzyme in the cholesterol biosynthesis pathway, targeted by statins to lower cholesterol levels. Autoantibodies against HMGCR were first identified in 2009 and are strongly associated with immune-mediated necrotizing myopathy (IMNM), particularly in statin-exposed individuals. These antibodies are detected in approximately 6% of idiopathic inflammatory myopathy cases and are a hallmark of statin-associated autoimmune myopathy.
The pathogenesis involves statins upregulating HMGCR expression in muscle cells, potentially triggering an autoimmune response in genetically susceptible individuals (e.g., those with *HLA-DRB1* alleles). HMGCR antibodies are IgG-specific and correlate with disease severity, aiding diagnosis when combined with clinical features like proximal muscle weakness, elevated creatine kinase, and muscle necrosis on biopsy.
Testing for HMGCR antibodies (via ELISA or immunoprecipitation) is crucial for differentiating IMNM from other myopathies. Treatment typically involves immunosuppressants (e.g., corticosteroids, rituximab) and statin discontinuation. Research continues to clarify mechanisms linking statins, autoimmunity, and muscle injury, enhancing diagnostic and therapeutic strategies.
×
